Skip to main content
OpenTrials

Clinical trial condition

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Explore clinical trials studying Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Study availability and eligibility vary by location and protocol.

297 public trials 56 recruiting studies
Refine in advanced search Browse all conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma trial results

Completed

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00243087

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +25 more
Locations
  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States
  • James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York, United States
  • M. D. Anderson Cancer Center at University of Texas Houston, Texas, United States
View Trial Details
Completed

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCT01626664

Conditions
Adult T-Cell Leukemia-Lymphoma, Hematologic Diseases, Hemic and Lymphatic Diseases, +12 more
Locations
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of Miami / Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Northwestern University Chicago, Illinois, United States
  • National Cancer Institute Bethesda, Maryland, United States
View all 20 locations
View Trial Details
Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

NCT02168140

Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, +40 more
Locations
  • Comprehensive Cancer Center of Wake Forest University Winston-Salem, North Carolina, United States
  • Abramson Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details

Related conditions